Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6547930 | 0.96 | MAPT (0.37) | ALDH1A1KMT2APRSS1TMPRSS15TSHR | |
| SCHEMBL6563804 | 0.92 | KMT2A (0.37) | ALDH1A1KMT2APRSS1TMPRSS15TSHR | |
| SCHEMBL6562349 | 0.90 | MAPT (0.42) | KMT2APRSS1TMPRSS15MAPT | |
| SCHEMBL6563555 | 0.85 | CYP2C9 (0.43) | ALDH1A1KMT2APRSS1TMPRSS15TSHR | |
| SCHEMBL6549016 | 0.83 | MAPT (0.47) | ALDH1A1KMT2APRSS1TSHRCCNC | |
| SCHEMBL6547027 | 0.81 | CA12 (0.46) | ALDH1A1 | |
| SCHEMBL6547031 | 0.81 | CA12 (0.46) | ALDH1A1 | |
| SCHEMBL9626606 | 0.80 | NPC1 (0.51) | KMT2APRSS1TSHRMAPTPOLB | |
| SCHEMBL6547911 | 0.80 | MAPT (0.42) | ALDH1A1KMT2APRSS1TSHRCCNC | |
| SCHEMBL6547272 | 0.80 | PDCD1 (0.44) | ALDH1A1KMT2APRSS1TSHRCCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730371-B2 | LIQUID CRYSTAL DISPLAY | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-05-04 | — | — | US | disclosed |
| EP-1249484-B1 | Optically active compound and liquid crystal composition containing the compound | MITSUBISHI GAS CHEMICAL CO (JP) | 2004-01-28 | — | — | EP | disclosed |
| US-20030054119-A1 | Optically active compound and liquid crystal composition containing the compound | MITSUBISHI GAS CHEMICAL CO., INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1249484-A1 | Optically active compound and liquid crystal composition containing the compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030054119-A1 | Optically active compound and liquid crystal composition containing the compound | HDHD5, THOC2, TDO2 | ALDH1A1 4758/4885KMT2A 3725/4885PRSS1 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.